Targeted delivery of siRNA reduces pulmonary fibrosis in mice, suggesting a new approach to treating lung diseases.
Targeted Fstl1 inhibition using siRNA significantly mitigated pulmonary fibrosis in a murine bleomycin model. The successful application of PLGA nanomaterials for siRNA delivery underscores their potential for safe and effective in vivo gene silencing. These findings highlight si-Fstl1 as a promising therapeutic candidate for IPF and support further investigation of RNA-based nanomedicine in fibrotic lung diseases.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: